GBT

全球血液疗法
NASDAQ

实时行情|Nasdaq Last Sale

49.60
+0.87
+1.79%
交易中 12:45 04/02 EDT
开盘
47.74
昨收
48.73
最高
50.29
最低
47.30
成交量
21.38万
成交额
--
52周最高
87.54
52周最低
39.95
市值
30.17亿
市盈率(TTM)
-10.9071
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GBT价格均价为99.63,最高价位150.00,最低价为60.00。

EPS

GBT 新闻

更多
  • 瑞幸就造假一事在内部发文:相关人员已停职并被接任
  • 新浪财经 · 21分钟前
  • “大空头”查诺斯:盘前回补了在瑞幸咖啡的空头头寸
  • 新浪美股 · 23分钟前
  • 英国央行新量化宽松计划将纳入价值120亿美元的企业债
  • 新浪美股 · 24分钟前
  • 美联储放松监管将赋予银行做市能力
  • 新浪美股 · 26分钟前

所属板块

生物技术和医学研究
+2.06%
制药与医学研究
+1.62%

热门股票

代码
价格
涨跌幅

GBT 简况

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
展开

微牛提供Global Blood Therapeutics Inc(NASDAQ-GBT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GBT股票新闻,以帮助您做出投资决策。